Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel C Javitt

Showing results (11-20 of 267) with videos related to

Pageof 27
Sort By:
International Review of Neurobiology|March 14, 2007
Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactionsDaniel C Javitt
Annual Review of Pharmacology and Toxicology|September 23, 2022
Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to TreatmentDaniel C Javitt
Current Opinion in Drug Discovery & Development|June 30, 2009
Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modificationDaniel C Javitt
Biological Psychiatry|December 18, 2007
Glycine transport inhibitors and the treatment of schizophreniaDaniel C Javitt
The American Journal of Psychiatry|October 1, 2021
Translational Mechanistic Biomarkers for the 21st CenturyDaniel C Javitt
The Israel Journal of Psychiatry and Related Sciences|August 6, 2010
Glutamatergic theories of schizophreniaDaniel C Javitt
JAMA Psychiatry|May 9, 2014
Distress intolerance, kynurenic acid, and schizophreniaDaniel C Javitt
Schizophrenia Bulletin|September 19, 2012
Twenty-five years of glutamate in schizophrenia: are we there yet?Daniel C Javitt
Current Opinion in Psychiatry|April 14, 2006
Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patientsDaniel C Javitt
The American Journal of Psychiatry|July 4, 2013
Harnessing N-methyl-d-aspartate receptors for new treatment development in psychiatry: positive lessons from negative studiesDaniel C Javitt
Pageof 27

Showing results (11-20 of 267) with videos related to

Sort By:
Pageof 27
International Review of Neurobiology|March 14, 2007
Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactionsDaniel C Javitt
Annual Review of Pharmacology and Toxicology|September 23, 2022
Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to TreatmentDaniel C Javitt
Current Opinion in Drug Discovery & Development|June 30, 2009
Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modificationDaniel C Javitt
Biological Psychiatry|December 18, 2007
Glycine transport inhibitors and the treatment of schizophreniaDaniel C Javitt
The American Journal of Psychiatry|October 1, 2021
Translational Mechanistic Biomarkers for the 21st CenturyDaniel C Javitt
The Israel Journal of Psychiatry and Related Sciences|August 6, 2010
Glutamatergic theories of schizophreniaDaniel C Javitt
JAMA Psychiatry|May 9, 2014
Distress intolerance, kynurenic acid, and schizophreniaDaniel C Javitt
Schizophrenia Bulletin|September 19, 2012
Twenty-five years of glutamate in schizophrenia: are we there yet?Daniel C Javitt
Current Opinion in Psychiatry|April 14, 2006
Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patientsDaniel C Javitt
The American Journal of Psychiatry|July 4, 2013
Harnessing N-methyl-d-aspartate receptors for new treatment development in psychiatry: positive lessons from negative studiesDaniel C Javitt
Pageof 27